Literature DB >> 7619999

Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study.

S Moreno1, M E García-Leoni, E Cercenado, M D Diaz, J C Bernaldo de Quirós, E Bouza.   

Abstract

To evaluate the incidence and the significance of resistance to erythromycin among clinical isolates of Streptococcus pneumoniae, we identified and prospectively followed all hospitalized patients in a 27-month period who had the organism isolated from any clinical sample. Patients who had an infection caused by pneumococci resistant to erythromycin (minimum inhibitory concentration, > 1 microgram/mL) were compared to those with infections caused by erythromycin-susceptible organisms. The incidence of erythromycin resistance among pneumococci doubled over the study period (from 7.6% in 1988 to 15.2% in 1992). Most strains (94%) showed resistance to multiple antibiotics, including other macrolides. By multivariate analysis, an age of < 5 years and nosocomial acquisition of the infection were independent risk factors for erythromycin resistance. Among patients with pneumococcal pneumonia caused by erythromycin-resistant organisms, 9 patients treated with third-generation cephalosporins were cured, while therapy with erythromycin failed for 2 of the 6 patients to whom it was administered. The rapid and significant increase of erythromycin resistance among clinical isolates of S. pneumoniae points to the need for routine surveillance of pneumococcal resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619999     DOI: 10.1093/clinids/20.5.1195

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

3.  Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.

Authors:  Holly L Hoffman; Michael E Klepser; Erika J Ernst; C Rosemarie Petzold; Loai Mohammed Sa'adah; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 4.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.

Authors:  Rie Isozumi; Yutaka Ito; Tadashi Ishida; Makoto Osawa; Toyohiro Hirai; Isao Ito; Ko Maniwa; Michio Hayashi; Hitoshi Kagioka; Masataka Hirabayashi; Koichi Onari; Hiromi Tomioka; Keisuke Tomii; Iwao Gohma; Seiichiro Imai; Shunji Takakura; Yoshitsugu Iinuma; Satoshi Ichiyama; Michiaki Mishima
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

6.  Ribosomal Resistance: Emerging Problems and Potential Solutions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

7.  Macrolide resistance in adults with bacteremic pneumococcal pneumonia.

Authors:  Joshua P Metlay; Neil O Fishman; Marshall M Joffe; Michael J Kallan; Jesse L Chittams; Paul H Edelstein
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

8. 

Authors:  M E García Leoni; B Macías Bou; L Martín González; E Martínez Larrull
Journal:  Medicine (Madr)       Date:  2011-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.